ZHAO Zhen-xia, ZHAO Zhen-min, LI Tong. Clinical Effect of Guirong Decoction Combined with Integration Scheme for Treating Stage 3-4 Chronic Kidney Disease and Impact on Cellular Immunity[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(21): 189-192.
ZHAO Zhen-xia, ZHAO Zhen-min, LI Tong. Clinical Effect of Guirong Decoction Combined with Integration Scheme for Treating Stage 3-4 Chronic Kidney Disease and Impact on Cellular Immunity[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(21): 189-192. DOI: 10.13422/j.cnki.syfjx.2015210189.
Objective: To investigate the clinical effect of Guirong decoction combined with integration scheme for treating stage 3-4 chronic kidney disease and the impact on cellular immunity. Method: Ninety-two patients with stage 3-4 chronic kidney disease hospitalized in our hospital from March 2010 to April 2013 were selected. All cases were randomly divided into Guirong decoction group (n=46) and conventional group (n=46). Patients in conventional group were given chronic renal failure integration treatment. Patients in Guirong decoction group were given Guirong decoction combined with integration scheme on the basis of conventional treatment measures. Respectively before treatment and after two months treatment
serum creatinine (SCr) and blood urea nitrogen (BUN) were tested
and corresponding eGFR values were calculated after follow-up. T cell subsets of CD4+
CD8+
CD4+/CD8+ were detected by flow cytometry. The cytokines interleukin-2 (IL-2) and IL-6 were detected by radioimmunoassay. Result: The 39 cases (84.8%) in Guirong decoction group and 41 (89.1%) cases in conventional group completed this treatment. The total efficiency of Guirong decoction group was 53.8%
significantly higher than 17.1% of the conventional group
with statistically significant difference (P<0.05). After 2 months treatment
the blood concentrations of SCr and BUN of Guirong decoction group were (240.5±49.8) μmol·L-1 and (9.8±3.9) mmol·L-1
lower than those in conventional group
while eGFR was (47.6±10.5) mL·(min·73 m2)-1
higher than that in conventional group
with statistically significant difference (P<0.05). CD4+ and CD4+/CD8+ of Guirong decoction group were (34.2±6.7)% and (1.6±0.2)
higher than those in conventional group
while CD8+ was (21.5±4.7)%
lower than that in the conventional group
with statistically significant difference (P<0.05). The level of IL-2 in Guirong decoction group was (19.6±6.3) mg·L-1
higher than that in the conventional group
while IL-6 was (115.3±22.4)mg·L-1
lower than that in conventional group
with statistically significant difference (P<0.05). Conclusion: The clinical effect of Guirong decoction combined with integration scheme for treating stage 3-4 chronic kidney disease was exact. It could effectively improve renal function and cellular immunity
thus helpful to improve the life quality of patients.